Financial Performance - The company's revenue for Q1 2024 was ¥2,973,005,617.76, a decrease of 8.01% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥23,170,466.54, down 85.54% year-over-year[5]. - The net profit after deducting non-recurring gains and losses was ¥23,536,277.50, representing an 83.01% decline from the previous year[5]. - The net profit for the current period is 76,393,132.63, a decrease from 254,851,363.05 in the previous period, representing a decline of approximately 70%[29]. - The total profit for the current period is 101,365,629.84, down from 355,241,974.73, indicating a decrease of about 71%[29]. - The operating profit for the current period is 102,858,253.38, compared to 360,492,005.57 in the previous period, reflecting a decline of approximately 71%[29]. - Basic earnings per share for the current period is 0.0371, down from 0.2557 in the previous period, indicating a decrease of approximately 85%[30]. - The total comprehensive income attributable to the parent company is 23,169,898.96, a significant drop from 160,273,989.61 in the previous period, representing a decline of about 86%[30]. - The total comprehensive income attributable to minority shareholders is 53,222,666.09, compared to 94,577,373.44 in the previous period, indicating a decrease of approximately 44%[30]. Cash Flow and Liquidity - The cash flow from operating activities was -¥266,945,833.56, a 16.71% increase in negative cash flow compared to last year[5]. - The cash flow from operating activities shows a net outflow of 266,945,833.56, compared to a net outflow of 228,725,675.95 in the previous period[30]. - The cash flow from investing activities resulted in a net outflow of 459,639,091.92, compared to a net outflow of 75,059,602.72 in the previous period[31]. - The cash flow from financing activities generated a net inflow of 35,668,498.90, contrasting with a net outflow of 301,079,035.95 in the previous period[31]. - Cash and cash equivalents decreased to CNY 2.27 billion from CNY 2.97 billion, reflecting a reduction in liquidity[24]. - Cash and cash equivalents at the end of the period amount to 2,256,555,242.50, down from 3,540,080,774.49 at the end of the previous period[31]. - Cash and cash equivalents at the end of Q1 2024 were not specified but are critical for assessing liquidity[48]. Assets and Liabilities - Total assets at the end of the reporting period were ¥17,855,213,090.08, a decrease of 0.47% from the end of the previous year[5]. - The company's total assets amounted to CNY 17,855,213,090.08, a slight decrease from CNY 17,939,311,256.63 at the end of the previous quarter[44]. - Total liabilities decreased to CNY 7,945,903,437.23 from CNY 8,034,531,783.60, indicating a reduction of 1.11%[44]. - Long-term receivables decreased by 38.98% to CNY 15.65 million due to the recovery of matured receivables[17]. - Long-term equity investments increased by 46.26% to CNY 980.51 million, primarily due to the acquisition of equity in an associate[17]. - The equity attributable to shareholders of the parent company was CNY 7,497,593,403.99, down from CNY 7,566,265,438.86[45]. Operational Highlights - The diagnostic services business generated revenue of ¥1,149,000,000, a decrease of 5.97% year-over-year, while ICL revenue was ¥1,071,000,000, showing a growth of 10.41%[8]. - The company is focusing on cost reduction and efficiency improvement through supply chain optimization and strategic business deepening[8]. - The company is increasing R&D investment in key disease areas and business model solutions, particularly in LDT, IVD, and digital intelligence[8]. - The company is accelerating its international business expansion to tap into overseas markets for its products and services[8]. - Research and development expenses decreased to CNY 72,330,627.47 in Q1 2024 from CNY 99,924,701.55 in Q1 2023, reflecting a reduction of 27.77%[45]. Shareholder Actions - The company repurchased 5,032,500 shares, accounting for 0.80% of the total share capital, with a total transaction amount of CNY 91.32 million[23]. - The company plans to use between CNY 100 million and CNY 200 million for share repurchase to implement employee stock ownership plans or equity incentives[23].

证券代码：300244 证券简称：迪安诊断 公告编号：2024-035 迪安诊断技术集团股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次会计政策变更是公司根据中华人民共和国财政部（以下简称"财政部"） 相关规定进行的变更，不会对公司财务状况、经营成果和现金流量产生重大影响。 2024 年 4 月 26 日，公司召开第五届董事会第六次会议和第五届监事会第四 次会议，审议通过了《关于会计政策变更的议案》，本次会计政策变更无需提交 股东大会，现将相关事宜公告如下： 一、会计政策变更概述 (二)变更前采用的会计政策 本次会计政策变更前，公司执行财政部颁布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告及其他相 关规定。 (一)会计政策变更的原因及时间 财政部于 2023 年 10 月 25 日公布了《企业会计准则解释第 17 号》（财会 〔2023〕21 号），规定了"关于流动负债与非流动负债的划分"、"关于供应商 融资安排的披露"、"关于售后租回交易的会计处理"，上述 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 20.00 CNY per share [3][14]. Core Insights - The company has shown a significant improvement in operating cash flow, with a net cash flow from operating activities of 1.921 billion CNY in 2023, an increase of 17.20% year-on-year [13]. - The conventional diagnostic services have demonstrated steady growth, with the diagnostic services segment generating revenue of 5.187 billion CNY in 2023, reflecting a year-on-year growth of 11.91% when excluding COVID-19 impacts [13]. - The company is expanding its business both domestically and internationally, with new projects and partnerships contributing to revenue growth [13]. Financial Summary - **Revenue**: The company reported revenue of 13.408 billion CNY in 2023, a decrease of 33.9% compared to 2022. Projections for 2024, 2025, and 2026 are 15.039 billion CNY, 16.925 billion CNY, and 19.106 billion CNY, respectively, indicating a recovery trend with expected growth rates of 12.2%, 12.5%, and 12.9% [2]. - **Net Profit**: The net profit attributable to the parent company was 307 million CNY in 2023, down 78.6% from 2022. Forecasts for the next three years are 785 million CNY, 989 million CNY, and 1.246 billion CNY, with significant growth expected in 2024 at 155.4% [2]. - **Earnings Per Share (EPS)**: The EPS for 2023 was 0.49 CNY, with projections of 1.25 CNY, 1.58 CNY, and 1.99 CNY for 2024, 2025, and 2026, respectively [2][14]. - **Profit Margins**: The gross margin for 2023 was 31.3%, with projections of 32.3%, 32.8%, and 33.3% for the following years [2]. The net margin was 2.3% in 2023, expected to improve to 5.2%, 5.8%, and 6.5% in the next three years [2]. Business Development - The company has launched 1,023 new testing projects and increased the number of tier-three hospital clients by 238, with tier-three hospital revenue accounting for 32.8% of total revenue [13]. - The company is also expanding its international presence, with plans to establish its first overseas ICL laboratory in Vietnam [13].

Investment Rating - The report maintains a "Recommended" rating for the company [10]. Core Views - The company reported a significant decline in revenue and net profit for 2023, with total revenue of 13.408 billion yuan, down 33.89%, and a net profit attributable to shareholders of 307.46 million yuan, down 78.56% [10]. - Despite the challenging operating environment, the company's core business remains resilient, particularly in diagnostic services, which saw an 11.91% increase in revenue to 5.187 billion yuan [10]. - The company has expanded its testing capabilities and product offerings, including new medical devices and diagnostic tests, which are expected to enhance its market position [10]. Financial Summary - The company’s projected financials for 2024-2026 include: - Revenue growth rates of 10.01%, 9.69%, and 8.87% respectively [12]. - Net profit forecasts of 774.35 million yuan, 973.34 million yuan, and 1.18288 billion yuan, reflecting growth rates of 151.85%, 25.70%, and 21.53% respectively [12]. - The projected EPS for the same period is 1.24 yuan, 1.55 yuan, and 1.89 yuan [12]. - The company’s gross margin is expected to improve from 31.29% in 2023 to 34.88% by 2026 [12].

ICL 业务延续良好增长，经营性现金流持续改善 | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------- ...

| --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Total assets of Hangzhou Dian Diagnostics reached CNY 8,144,514,711.30, with net assets attributable to the parent company at CNY 3,148,982,457.11 as of December 31, 2023[8]. - Hangzhou Dian achieved operating revenue of CNY 5,149,026,068.90, with an operating profit of CNY 191,131,541.38 and a net profit attributable to the parent company of CNY 106,998,915.85 during the reporting period[8]. - Beijing United Zhixin Medical Technology reported total assets of CNY 1,047,227,337.90 and net assets attributable to the parent company of CNY 652,661,688.69 as of December 31, 2023[9]. - Operating revenue for Beijing United Zhixin was CNY 1,037,203,032.30, with an operating profit of CNY 201,915,188.85 and a net profit attributable to the parent company of CNY 128,072,781.98[9]. - Qingdao Zhiying Medical Technology's total assets amounted to CNY 1,486,877,560.96, with net assets attributable to the parent company at CNY 944,877,879.25 as of December 31, 2023[13]. - The company reported operating revenue of CNY 1,553,391,719.19, with an operating profit of CNY 118,245,819.51 and a net profit attributable to the parent company of CNY 87,069,869.01 during the reporting period[13]. - Guangzhou Dihui Medical Device achieved total assets of CNY 1,148,238,169.25 and net assets attributable to the parent company of CNY 826,197,255.71 as of December 31, 2023[13]. - The operating revenue for Guangzhou Dihui was CNY 1,134,185,387.51, with an operating profit of CNY 124,470,407.76 and a net profit attributable to the parent company of CNY 88,429,305.98[13]. - The company reported a significant decline in net profit for the third quarter of 2023, with a loss of ¥223,417,843.36[116]. - The net profit attributable to shareholders for 2023 was ¥307,461,061.38, down 78.56% from ¥1,434,191,144.16 in 2022[115]. - The basic earnings per share for 2023 was ¥0.4918, a decline of 78.64% compared to ¥2.3022 in 2022[115]. - The total assets at the end of 2023 were ¥17,939,311,256.63, a decrease of 14.80% from ¥21,055,969,393.06 at the end of 2022[115]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth[95]. - The company reported a revenue of 1.2 billion RMB for the fiscal year 2023, representing a year-over-year growth of 15%[81]. Strategic Initiatives - The company has established several new subsidiaries, including Chengdu Dianrongkang Medical Device and Dian Diagnostics Vietnam Company Limited, which are expected to enhance market presence[5][7]. - The company continues to focus on expanding its market through strategic acquisitions and new product development initiatives[5][7]. - The company launched a five-year strategic plan in 2020, positioning itself as a provider of integrated medical diagnostic solutions, focusing on technological and business model innovations[14]. - In 2024, the company aims to enhance operational quality and profitability through strategic business deepening, particularly in precision centers and collaborative models, while targeting key projects in hematology, pathogen molecules, and neuroimmunology[18]. - The company plans to increase R&D investment, focusing on LDT, IVD, and digital intelligence, to expand its product line and enhance core competitiveness[18]. - The company is focusing on building a digital organization and improving customer experience through digitalization initiatives[38]. - The company aims to enhance its customer relationship management (CRM) system to improve user engagement and retention[81]. - The company is exploring potential acquisitions to bolster its service offerings, with a budget of 500 million RMB set aside for this purpose[95]. - The company is actively participating in the reform of the Chinese medical system, leveraging its strong R&D capabilities and flexible service models[179]. Market Expansion - The first overseas laboratory has been established in Vietnam, marking the company's entry into the Southeast Asian market, with plans to expand into Malaysia, Hong Kong, Thailand, Indonesia, Saudi Arabia, and the UAE[19]. - The company aims to enhance its international presence, with its subsidiary expanding laboratory services to multiple countries and officially opening a laboratory in Vietnam[38]. - The company is expanding its market presence in Southeast Asia, aiming for a 25% market share by 2025[81]. - The company plans to leverage its operational base in Urumqi to expand its business into Central Asia and the Middle East[38]. - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the call[66]. Research and Development - The company has achieved a 100% inclusion rate of its assets and revenues in the internal control evaluation scope, indicating comprehensive coverage[159]. - The company has completed the development of a multi-pathogen detection kit (Dano-seq V3.0) using nanopore sequencing, which aims to provide rapid and accurate pathogen detection results for common clinical pathogens[196]. - The company is currently developing a molecular POCT system for tuberculosis and non-tuberculous mycobacterium nucleic acid detection, targeting rapid on-site analysis to meet clinical needs[196]. - Ongoing research and development efforts are focused on enhancing existing technologies, with an investment of 100 million RMB allocated for the upcoming year[95]. - Research and development investment increased by 18%, focusing on innovative testing technologies[81]. - The company has successfully completed the development of a digital transaction project to enhance order management efficiency, aiming for full group rollout in 2024[200]. - The company has launched a clinical big data platform project, collaborating with 7 hospitals to provide integrated solutions for clinical data management and analysis[200]. - The company has completed the development of a multi-color digital PCR technology platform, which will expand its special testing product line for clinical services[200]. - The company is focusing on expanding its product line in tuberculosis testing to improve early screening and diagnosis, which is expected to boost performance[196]. - The company aims to establish a high-sensitivity detection system for drug-resistant diagnosis, enhancing its core competitiveness in the market[196]. Governance and Compliance - The company has established a governance system to ensure scientific decision-making and risk prevention, including the formation of a board advisory committee and various management teams[32]. - The company has a governance structure that complies with relevant laws and regulations, ensuring independent operation of the board and supervisory committee[60]. - The company has a total of 9 board members, including 3 independent directors, ensuring compliance with governance requirements[56]. - The company has established an internal audit system to oversee the authenticity and completeness of financial information[57]. - The company has established a risk management committee to strengthen quality culture and ensure compliance across all business segments[33]. - The company is committed to balancing the interests of shareholders, employees, and society, promoting sustainable and healthy development[57]. - The company has not reported any discrepancies between net profit and net assets under domestic and overseas accounting standards[147]. - The company has not reported any dissenting opinions from board members on significant matters during the reporting period[107]. - The company has maintained normal performance in fulfilling its commitments related to share transfer and related party transactions[171]. Human Resources - The total number of employees at the end of the reporting period was 10,843, with 4,732 being technical staff[125]. - The company has established six training bases across major cities in China to enhance employee skills, focusing on a "one-three-five-seven" talent development system[130]. - The company has optimized the "Qingzhu 2.0 Training Project" and the "One-Three-Five-Seven Talent Development System" to guide employee career development effectively[134]. - The company has a clear strategy for talent acquisition and retention, recognizing the importance of skilled professionals in maintaining innovation and growth[49]. - The company implemented a comprehensive compensation strategy based on position, performance, and capability, ensuring a competitive salary system to motivate employees[129]. Risks and Challenges - The company acknowledges potential risks related to diagnostic service quality, management, and regulatory compliance as it navigates the evolving healthcare landscape[20]. - The company is in a rapid growth phase, but increasing competition and new business models may lead to longer customer settlement cycles and increased accounts receivable, posing a risk of bad debts[50]. - The company is enhancing accounts receivable management by establishing a tracking mechanism and strengthening customer credit assessments to reduce the risk of bad debts[50]. - The company has not identified any significant or important deficiencies in its financial reporting controls during the self-inspection conducted in 2023[143]. Corporate Social Responsibility - The company is not classified as a key pollutant discharge unit and has not faced any penalties related to environmental protection laws during the reporting period[163]. - The company has not disclosed any measures taken to reduce carbon emissions during the reporting period[163]. - The company has not engaged in any activities related to poverty alleviation or rural revitalization during the reporting period[165]. - The company is actively involved in addressing corruption in the medical field, contributing to a healthier industry environment[184].

本人作为迪安诊断技术集团股份有限公司（以下简称"公司"）的独立董事， 在任职期间严格按照《公司法》《证券法》《上市公司独立董事规则》《深圳证券 交易所上市公司自律监管指引第2号——创业板上市公司规范运作》《公司章程》 《独立董事制度》等相关法律、法规、规章的规定和要求，在2023年度工作中， 诚实、勤勉、独立地履行职责，积极出席相关会议，认真审议董事会各项议案， 对公司重大事项发表了独立意见，充分发挥了独立董事及各专业委员会的作用。 现就本人2023年度履行独立董事职责情况汇报如下： 一、出席董事会及股东大会情况 2023年度，公司董事会会议、股东大会的召集召开符合法定程序，重大经营 决策和其他重大事项均按相关规定履行了相关程序，合法有效。 迪安诊断技术集团股份有限公司 独立董事蒋斌先生 2023 年度述职报告 各位股东及股东代表： 报告期内，公司共召开8次董事会，本人应参加3次，均亲自通过现场或通讯 方式出席参与表决，也没有缺席且未委托其他独立董事代为出席应出席会议并行 使表决权的情形。公司股东大会共召开2次会议。 | | | | 出席董事会情况 | | | | --- | --- | --- | --- ...

证券代码：300244 证券简称：迪安诊断 公告编号：2024-024 迪安诊断技术集团股份有限公司 关于 2023 年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2024 年 4 月 18 日，迪安诊断技术集团股份有限公司（以下简称"公司"） 召开第五届董事会第五次会议和第五届监事会第三次会议，审议通过了《关于 2023 年度计提资产减值准备的议案》，现将相关情况公告如下： 一、本次计提资产减值准备情况概述 （一）本次计提资产减值准备的原因 为真实反映公司财务状况和经营成果，本着谨慎性原则，依据《企业会计准 则》及公司会计政策的相关规定，公司对 2023 年末应收款项、存货、固定资产、 长期股权投资、在建工程、无形资产、商誉等资产进行了全面清查，对各项资产 减值的可能性、各类存货的可变现净值等进行了充分的评估和分析。 （二）本次计提资产减值准备的资产范围及金额 公司对 2023 年度末存在可能发生减值迹象的资产进行全面清查和资产减值 测试后，计提 2023 年度各项资产减值准备共计 39,981.90 万元。详情如下表： 单位： ...

证券代码：300244 证券简称：迪安诊断 公告编号：2024-026 迪安诊断技术集团股份有限公司 关于拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2024 年 4 月 18 日，迪安诊断技术集团股份有限公司(以下简称"公司")召 开第五届董事会第五次会议、第五届监事会第三次会议，审议通过了《关于续聘 会计师事务所的议案》，拟续聘立信会计师事务所（特殊普通合伙）（以下简称"立 信会计师事务所"或"立信"）为公司 2024 年度审计机构。本议案尚需提交公司 股东大会审议，现将有关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 （5）执行事务合伙人：杨志国、朱建弟 截至 2023 年末，立信拥有合伙人 278 名、注册会计师 2,533 名、从业人员 总数 10,730 名、签署过证券服务业务审计报告的注册会计师 693 名。 立信 2023 年业务收入（经审计）50.01 亿元，其中审计业务收入 35.16 亿元， 证券业务收入 17.65 亿元。 2023 年度立信为 671 家上市公司提供年报审 ...